Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Previous issues

Page Path
HOME > Browse articles > Previous issues
12 Previous issues
Filter
Filter
Article category
Keywords
Authors
Volume 34(2); April 2002
Prev issue Next issue
Original Articles
Annual Report of the Korea Central Cancer Registry Program 2000: Based on Registered Data from 131 Hospitals
Jong Myon Bae, Young Joo Won, Kyu Won Jung, Jae Gahb Park
Cancer Res Treat. 2002;34(2):77-83.   Published online April 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.2.77
AbstractAbstract PDF
PURPOSE
The Korea Central Cancer Registry (KCCR) program completed a nationwide hospital-based cancer registry to provide basic statistical data on cancer incidence.
MATERIALS AND METHODS
In 2000, 131 hospitals participated in the KCCR program. All cancer registry data, which were submitted by the participating hospitals during the year, were reviewed and analyzed by the committee members.
RESULTS
Of the 94,474 cases that were registered, 7,735 (8.2%) duplication cases were excluded. Of the remaining 86,739 cases, 2,893 cases (3.3%) of carcinoma in situ (morphology code/2) were excluded, leaving a final total of 83,846 cases for analysis, 48,005 (57.3%) male and 35,841 (42.7%) female. The leading age group was 60-64years (15.1%). The six leading primary cancer sites in the order of their relative frequency were the stomach (20.8%), lung (12.2%), liver (12.2%), colorectum (10.3%), breast (6.5%), and uterine cervix (4.5%). In males, the three leading primary cancer sites were the stomach (24.5%), liver (16.3%), and lung (16.3%). In females, the stomach (15.8%), breast (15.1%), and uterine cervix (10.6%). Among the 1,126 cases of childhood malignancies, leukemia (32.7%) was the most common cancer type.
CONCLUSION
We report our analysis of the KCCR data from 131 nationwide hospitals during 2000.

Citations

Citations to this article as recorded by  
  • Morin Hydrate Sensitizes Hepatoma Cells and Xenograft Tumor towards Cisplatin by Downregulating PARP-1-HMGB1 Mediated Autophagy
    Mahendra Pal Singh, Tejinder Pal Khaket, Vivek K. Bajpai, Saleh Alfarraj, Se-Gie Kim, Lei Chen, Yun Suk Huh, Young-Kyu Han, Sun Chul Kang
    International Journal of Molecular Sciences.2020; 21(21): 8253.     CrossRef
  • Helicobacter pyloriInfection and Intestinal Metaplasia among Healthy Adolescents
    Ji Sook Park, Kyuyol Rhie, Ji-Hyun Seo, Eo Young Ryu, Hyun-Jin Kim, Hong-Jun Kim, Jae-Young Lim, Hyang-Ok Woo, Seung-Chul Baik, Woo-Kon Lee, Myung-Je Cho, Kwang-Ho Rhee, Gyung-Hyuck Ko, Hee-Shang Youn
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2015; 15(4): 243.     CrossRef
  • Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer
    In Gyu Hwang, Joung-Soon Jang, Sung Yong Oh, Myung Hwan Rho, Suee Lee, Young Suk Park, Joon Oh Park, Eun Mi Nam, Hyo Rak Lee, Hyun Jung Jun, Kyong-Choun Chi
    Cancer Chemotherapy and Pharmacology.2015; 75(4): 757.     CrossRef
  • Clinical Significance of IGFBP-3 Methylation in Patients with Early Stage Gastric Cancer
    Seung Tae Kim, Hye-Lim Jang, Jeeyun Lee, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Min Gew Choi, Jae Moon Bae, Tae Sung Sohn, Jae Hyung Noh, Sung Kim, Kyoung-Mee Kim, Won Ki Kang, Joon Oh Park
    Translational Oncology.2015; 8(4): 288.     CrossRef
  • Outcomes of advanced gastric cancer in young adult patients treated with first-line combination chemotherapy
    Hyun-Jun Kim, Kyoung Kim
    International Journal of Cancer Therapy and Oncology.2015; 3(4): 344.     CrossRef
  • Pazopanib, a Novel Multitargeted Kinase Inhibitor, Shows PotentIn VitroAntitumor Activity in Gastric Cancer Cell Lines withFGFR2Amplification
    Seung Tae Kim, Hye-Lim Jang, Su Jin Lee, Jeeyun Lee, Yoon-La Choi, Kyoung-Mee Kim, Jeonghee Cho, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Masakazu Yashiro, Won Ki Kang, Joon Oh Park
    Molecular Cancer Therapeutics.2014; 13(11): 2527.     CrossRef
  • A Novel Proteomics-Based Clinical Diagnostics Technology Identifies Heterogeneity in Activated Signaling Pathways in Gastric Cancers
    Jeeyun Lee, Sung Kim, Phillip Kim, Xinjun Liu, Tani Lee, Kyoung-Mee Kim, In-Gu Do, Joon Oh Park, Se Hoon Park, Jiryeon Jang, Nicholas Hoe, Gulia Harvie, Anne Kuller, Anjali Jain, Gary Meyer, Glen Leesman, Young Suk Park, Min Gew Choi, Tae Sung Sohn, Jae M
    PLoS ONE.2013; 8(1): e54644.     CrossRef
  • Plasma human mammaglobin mRNA associated with poor outcome in patients with breast cancer
    G.-W. Lee, J.-Y. Kim, E.-H. Koh, D. Kang, D.S. Choi, K.-Y. Maeng, J.-S. Lee
    Genetics and Molecular Research.2012; 11(4): 4034.     CrossRef
  • P21-Activated Kinase 4 Overexpression in Metastatic Gastric Cancer Patients
    Hee Kyung Ahn, Jiryeon Jang, Jeeyun Lee, Hoon Park Se, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Kyoung-Mee Kim, Won Ki Kang
    Translational Oncology.2011; 4(6): 345.     CrossRef
  • Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer
    Taekyu Lim, Jeeyun Lee, Duk Joo Lee, Ha Yeon Lee, Boram Han, Kyung Kee Baek, Hee Kyung Ahn, Su Jin Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Kyoung-Mee Kim, Won Ki Kang
    Cancer Chemotherapy and Pharmacology.2011; 68(1): 255.     CrossRef
  • Prognostic Factors in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Retrospective Comparison with Previously Known Prognostic Models
    Kyung Kee Baek, Jung-Hoon Kim, Ji Eun Uhm, Se Hoon Park, Jeeyun Lee, Joon Oh Park, Young Suk Park, Won Ki Kang, Ho Yeong Lim
    Oncology.2011; 80(3-4): 167.     CrossRef
  • A phase II study of mitomycin-C and S-1 as third-line chemotherapy in patients with advanced colorectal cancer
    JUNG HAN KIM, HYEONG SU KIM, DAE RO CHOI, GEUNDOO JANG, JUNG HYE KWON, HO YOUNG KIM, JOO YOUNG JUNG, HYO JUNG KIM, HUN HO SONG, YUN HO SHIN, SO YOUNG JUNG, BYUNG CHUN KIM, DAE YOUNG ZANG
    Oncology Letters.2011; 2(6): 1253.     CrossRef
  • Effect of Benzothiazole based conjugates in causing apoptosis by Regulating p53, PTEN and MAP Kinase proteins affecting miR-195a and miR-101-1
    SNCVL Pushpavalli, M Janaki Ramaiah, Ch Srinivas, Debasmita Mukhopadhya, JL Aditya, Ravindra M Kumbhare, Utpal Bhadra, Manika Pal Bhadra
    Cancer Cell International.2011;[Epub]     CrossRef
  • Phase II study of a biweekly schedule of docetaxel and cisplatin in patients with metastatic non-small cell lung cancer
    Su-Hee Cho, Se-Il Go, Gyeong-Won Lee, Jung Hun Kang, Hoon-Gu Kim, Seok Hyun Kim, Yu Ji Cho, Yi Yeong Jeong, Ho-Cheol Kim, Jong Duk Lee, Young Sil Hwang
    Lung Cancer.2010; 69(1): 94.     CrossRef
  • Lung cancer risk and cigarette smoking, lung tuberculosis according to histologic type and gender in a population based case–control study
    Sue K. Park, Lisa Y. Cho, Jae Jeong Yang, Boyoung Park, Soung Hoon Chang, Kun-Sei Lee, Hyeongsu Kim, Keun-Young Yoo, Choon-Taek Lee
    Lung Cancer.2010; 68(1): 20.     CrossRef
  • Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer
    Jung Hye Kwon, Jung Han Kim, Jung-Ae Lee, Hyun Chun Shin, Hyo Jung Kim, Hun Ho Song, Joo Young Jung, Ho Young Kim, Dae Ro Choi, Hyeong Su Kim, Young-iee Park, Dae Young Zang
    Cancer Chemotherapy and Pharmacology.2010; 66(5): 889.     CrossRef
  • Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer
    Hyo Jin Lee, Do Yeun Cho, Ji Chan Park, Sang Byung Bae, Kyu Taek Lee, In Sung Cho, Chang Soon Han, Suk Young Park, Hwan Jung Yun, Samyong Kim
    Cancer Chemotherapy and Pharmacology.2009; 63(3): 427.     CrossRef
  • Phase II study of S-1 and irinotecan combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Korean Cancer Study Group Protocol ST05-02
    Hye J KANG, Sang H CHO, Suk J OH, Sung H YANG, Moon H LEE, Eun-Kee SONG, Hyun C CHUNG, Im I NA, Baek-Yeol RYOO
    Asia-Pacific Journal of Clinical Oncology.2009; 5(1): 46.     CrossRef
  • A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma
    Ji Eun Uhm, Joon Oh Park, Jeeyun Lee, Young Suk Park, Se Hoon Park, Byung Chul Yoo, Seung Woon Paik, Kwang Cheol Koh, Won Ki Kang, Ho Yeong Lim
    Cancer Chemotherapy and Pharmacology.2009; 63(5): 929.     CrossRef
  • Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
    Seong Yoon Yi, Young Suk Park, Hyo Song Kim, Hyun Jung Jun, Kyoung Ha Kim, Myung Hee Chang, Min Jae Park, Ji Eun Uhm, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Jong Kyun Lee, Kyu Taek Lee, Ho Yeong Lim, Won Ki Kang
    Cancer Chemotherapy and Pharmacology.2009; 63(6): 1141.     CrossRef
  • A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer
    Kyoung Ha Kim, Young Suk Park, Myung Hee Chang, Hyo Song Kim, Hyun Jung Jun, Jieun Uhm, Seong Yoon Yi, Do Hyoung Lim, Sang Hoon Ji, Min Jae Park, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Ho Yeong Lim, Won Ki Kang
    Cancer Chemotherapy and Pharmacology.2009; 64(2): 347.     CrossRef
  • A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer
    Sang Hoon Ji, Do Hyoung Lim, Seong Yoon Yi, Hyo Song Kim, Hyun Jung Jun, Kyoung Ha Kim, Myung Hee Chang, Min Jae Park, Ji Eun Uhm, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
    BMC Cancer.2009;[Epub]     CrossRef
  • Impact of Standardized Rhus verniciflua Stokes Extract as Complementary Therapy on Metastatic Colorectal Cancer: A Korean Single-Center Experience
    Sang-hun Lee, Won-cheol Choi, Seong-woo Yoon
    Integrative Cancer Therapies.2009; 8(2): 148.     CrossRef
  • Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma
    Dongho Choi, Hyo Won Lee, Kyung Yul Hur, Jae Joon Kim, Gyeong-Sin Park, Si-Hyong Jang, Young Soo Song, Ki-Seok Jang, Seung Sam Paik
    World Journal of Gastroenterology.2009; 15(18): 2258.     CrossRef
  • Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy
    Se Hoon Park, Moon Sook Cho, Young Saing Kim, Junshik Hong, Eunmi Nam, Jinny Park, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee, Woon Kee Lee
    Quality of Life Research.2008; 17(2): 207.     CrossRef
  • Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study
    Se Hoon Park, Young Saing Kim, Junshik Hong, Jinny Park, Eunmi Nam, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee, Woon Kee Lee, Min Chung
    Anti-Cancer Drugs.2008; 19(3): 303.     CrossRef
  • A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer
    H J Kang, H M Chang, T W Kim, M-H Ryu, H-J Sohn, J H Yook, S T Oh, B S Kim, J-S Lee, Y-K Kang
    British Journal of Cancer.2008; 98(2): 316.     CrossRef
  • Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study
    Yeul Hong Kim, Hyun Cheol Chung, Won Ki Kang, Sook Ryun Park, Chul Soo Kim, Tae-Yue Kim, Sang Won Shin, Byung-Joo Park, Soo Jin Cha, Yung-Jue Bang
    Cancer Chemotherapy and Pharmacology.2008; 62(2): 263.     CrossRef
  • Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer
    Se Hoon Park, Junshik Hong, Young Saing Kim, Yujin Kim, Sun Young Kyung, Chang Hyeok An, Sang Pyo Lee, Jeong Woong Park, Sung Hwan Jeong, Jinny Park, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
    Lung Cancer.2008; 62(1): 72.     CrossRef
  • Comparison of the 13C-urea breath test and the endoscopic phenol red mucosal pH test in the quantification of Helicobacter pylori infection loading
    Young-Seok Cho, Hiun-Suk Chae, Se Na Jang, Jin-Soo Kim, Hye Suk Son, Hyung-Keun Kim, Byung-Wook Kim, Sok-Won Han, Kyu-Yong Choi, Hae Kyung Lee, Eun Deok Chang
    The Korean Journal of Internal Medicine.2008; 23(3): 134.     CrossRef
  • Salvage Chemotherapy With Biweekly Irinotecan, Plus 5-Fluorouracil and Leucovorin in Patients With Advanced Gastric Cancer Previously Treated With Fluoropyrimidine, Platinum, and Taxane
    Sun Jin Sym, Min-Hee Ryu, Jae-Lyun Lee, Heung Moon Chang, Tae Won Kim, Sung Sook Lee, Jung Shin Lee, Yoon-Koo Kang
    American Journal of Clinical Oncology.2008; 31(2): 151.     CrossRef
  • Adenosine Kinase Gene Expression in Human Colorectal Cancer
    S. Giglioni, R. Leoncini, E. Aceto, A. Chessa, S. Civitelli, A. Bernini, G. Tanzini, F. Carraro, A. Pucci, D. Vannoni
    Nucleosides, Nucleotides and Nucleic Acids.2008; 27(6-7): 750.     CrossRef
  • Impact of E2F-1 Expression on Clinical Outcome of Gastric Adenocarcinoma Patients with Adjuvant Chemoradiation Therapy
    Jeeyun Lee, Cheol Keun Park, Joon Oh Park, Taekyu Lim, Young Suk Park, Ho Yeong Lim, Inkyoung Lee, Tae Sung Sohn, Jae Hyung Noh, Jin Seok Heo, Sung Kim, Do Hoon Lim, Kyoung-Mee Kim, Won Ki Kang
    Clinical Cancer Research.2008; 14(1): 82.     CrossRef
  • Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma
    Jeeyun Lee, Kee‐Taek Jang, Chang‐Seok Ki, Taekyu Lim, Young Suk Park, Ho Yeong Lim, Dong‐Wook Choi, Won Ki Kang, Keunchil Park, Joon Oh Park
    Cancer.2007; 109(8): 1561.     CrossRef
  • Risk factor stratification after simultaneous liver and colorectal resection for synchronous colorectal metastasis
    Won-Suk Lee, Min Jung Kim, Seong Hyeon Yun, Ho-Kyung Chun, Woo Yong Lee, Sung-Joo Kim, Seong-Ho Choi, Jin-Seok Heo, Jae Won Joh, Yong Il Kim
    Langenbeck's Archives of Surgery.2007; 393(1): 13.     CrossRef
  • Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first‐line therapy in advanced nonsmall cell lung cancer
    Se Hoon Park, Soo Jin Choi, Sun Young Kyung, Chang Hyeok An, Sang Pyo Lee, Jeong Woong Park, Sung Hwan Jeong, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
    Cancer.2007; 109(4): 732.     CrossRef
  • A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer
    Bong-Gun Seo, Sung Yong Oh, Dong Mee Lee, Hyun Seung Yoo, Suee Lee, Seong-Geun Kim, Sung-Hyun Kim, Hyuk-Chan Kwon, Hyo-Jin Kim
    Cancer Research and Treatment.2007; 39(1): 6.     CrossRef
  • Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer
    Jae Yun Lim, Jae Yong Cho, Yong Han Paik, Dong Ki Lee, Sang In Lee, Hyo Jin Park, Se Joon Lee, Kwan Sik Lee, Dong Sup Yoon, Seung Ho Choi
    Oncology.2007; 73(1-2): 2.     CrossRef
  • Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma
    J. Lee, W.K. Kang, J.M. Kwon, S.Y. Oh, H.R. Lee, H.J. Kim, B.B. Park, H.Y. Lim, M.J. Han, J.O. Park, Y.S. Park
    Annals of Oncology.2007; 18(1): 88.     CrossRef
  • Malignancies in Korean Patients with Inflammatory Myopathy
    Sang-Won Lee, Sang Youn Jung, Min-Chan Park, Yong-Beom Park, Soo-Kon Lee
    Yonsei Medical Journal.2006; 47(4): 519.     CrossRef
  • Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma
    Se Hoon Park, Yeon Ho Park, Jeong Nam Lee, Soo‐Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
    Cancer.2006; 106(2): 361.     CrossRef
  • The Synergism between Belotecan and Cisplatin in G astric Cancer
    Joo Young Jung, Sang Hyun Song, Tae-Young Kim, Jung Hyun Park, Hyun-Soon Jong, Seock-Ah Im, Tae-You Kim, Yung-Jue Bang, Noe Kyoung Kim
    Cancer Research and Treatment.2006; 38(3): 159.     CrossRef
  • Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil
    Se Hoon Park, Woon Kee Lee, Min Chung, Yuna Lee, Sang Hoon Han, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
    Anti-Cancer Drugs.2006; 17(2): 225.     CrossRef
  • Thalidomide for Treating Metastatic Hepatocellular Carcinoma: A Pilot Study
    Sang Hoon Han, Se Hoon Park, Jung Ho Kim, Jong Jun Lee, So Young Kwon, Oh Sang Kwon, Sun Suk Kim, Ju Hyun Kim, Keon Kug Kim, Yeon Ho Park, Jeong Nam Lee, Eunmi Nam, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
    The Korean Journal of Internal Medicine.2006; 21(4): 225.     CrossRef
  • Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer
    Se Hoon Park, Jeeyun Lee, Se Hoon Lee, Joon Oh Park, Kihyun Kim, Won Seog Kim, Chul Won Jung, Young Suk Park, Won Ki Kang, Keunchil Park, Seonwoo Kim, Soo Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
    Cancer Chemotherapy and Pharmacology.2006; 57(1): 91.     CrossRef
  • A Pilot Study of Cisplatin, Irinotecan, Leucovorin and 5-fluorouracil (PILF) Combination Chemotherapy for Advanced Gastric Cancer
    Se Hoon Park, Soo Yeon Jeon, Kwang Il Ko, Eunmi Nam, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee, Woon Ki Lee, Min Chung
    Cancer Research and Treatment.2006; 38(3): 121.     CrossRef
  • Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy
    Se Hoon Park, Woon Ki Lee, Min Chung, Soo-Mee Bang, Eun Kyung Cho, Jae Hoon Lee, Dong Bok Shin
    Cancer Chemotherapy and Pharmacology.2006; 57(3): 289.     CrossRef
  • Progression of Atrophic Gastritis and Intestinal Metaplasia Drives Helicobacter pylori Out of the Gastric Mucosa
    Hae Yeon Kang, Nayoung Kim, Young Soo Park, Jin-Hyeok Hwang, Jin-Wook Kim, Sook Hyang Jeong, Dong Ho Lee, Hyun Chae Jung, In Sung Song
    Digestive Diseases and Sciences.2006; 51(12): 2310.     CrossRef
  • Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma
    Se Hoon Park, Yuna Lee, Sang Hoon Han, So Young Kwon, Oh Sang Kwon, Sun Suk Kim, Ju Hyun Kim, Yeon Ho Park, Jeong Nam Lee, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
    BMC Cancer.2006;[Epub]     CrossRef
  • Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer
    Keon Woo Park, Jin Seok Ahn, Young Suk Park, Jeeyun Lee, Jung Hoon Kang, Joon Oh Park, Ho Yeong Lim, Young-Hyuck Im, Won Ki Kang, Keunchil Park, Soon Il Lee
    Cancer Chemotherapy and Pharmacology.2006; 59(1): 17.     CrossRef
  • Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil and Low Dose Leucovorin in Patients with Advanced Colorectal Cancer
    Yoon Mi Shin, Hae Suk Han, Seong Woo Lim, Byung Chul Kim, Kyung Suck Cheoi, Young Ook Eum, Seung Taek Kim, Ki Hyeong Lee
    Cancer Research and Treatment.2005; 37(5): 284.     CrossRef
  • Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy
    H J Kang, H M Chang, T W Kim, M-H Ryu, H J Sohn, J H Yook, S T Oh, B S Kim, J-S Lee, Y-K Kang
    British Journal of Cancer.2005; 92(2): 246.     CrossRef
  • A Phase II Study of Epirubicin, Cisplatin and Capecitabine Combination Chemotherapy in Patients with Metastatic or Advanced Gastric Cancer
    Eun Kyung Cho, Woon Ki Lee, Seok-Ah Im, Soon Nam Lee, Se Hoon Park, Soo-Mee Bang, Dong Kyun Park, Yeon Ho Park, Dong Bok Shin, Jae Hoon Lee
    Oncology.2005; 68(4-6): 333.     CrossRef
  • Interleukin‐1B (IL‐1B) polymorphisms and gastric mucosal levels of IL‐1β cytokine in Korean patients with gastric cancer
    Young‐Woon Chang, Jae‐Young Jang, Nam‐Hoon Kim, Jae Won Lee, Hyo Jung Lee, Woon Won Jung, Seok‐Ho Dong, Hyo‐Jong Kim, Byung‐Ho Kim, Joung‐Il Lee, Rin Chang
    International Journal of Cancer.2005; 114(3): 465.     CrossRef
  • Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer
    S C Oh, K H Park, I K Choi, S Y Yoon, S J Kim, J H Seo, C W Choi, B S Kim, S W Shin, J S Kim, Y H Kim
    British Journal of Cancer.2005; 92(5): 827.     CrossRef
  • Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer
    Se Hoon Park, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee, Woon KI Lee, Min Chung
    BMC Cancer.2005;[Epub]     CrossRef
  • An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach
    Sung Kim, Do Hoon Lim, Jeeyun Lee, Won Ki Kang, John S. MacDonald, Chan Hyung Park, Se Hoon Park, Se-Hoon Lee, Kihyun Kim, Joon Oh Park, Won Seog Kim, Chul Won Jung, Young Suk Park, Young-Hyuck Im, Tae Sung Sohn, Jae Hyung Noh, Jin Seok Heo, Yong Il Kim,
    International Journal of Radiation Oncology*Biology*Physics.2005; 63(5): 1279.     CrossRef
  • Oxaliplatin, Folinic Acid and 5-Fluorouracil (FOLFOX-4) Combination Chemotherapy as Second-line Treatment in Advanced Colorectal Cancer Patients with Irinotecan Failure: A Korean Single-center Experience
    Se Hoon Park, Ju Young Sung, Sang-Hoon Han, Jeong Heum Baek, Jae Hwan Oh, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
    Japanese Journal of Clinical Oncology.2005; 35(9): 531.     CrossRef
  • CASPASE-8 Gene Is Inactivated by Somatic Mutations in Gastric Carcinomas
    Young Hwa Soung, Jong Woo Lee, Su Young Kim, Jin Jang, Yong Gyu Park, Won Sang Park, Suk Woo Nam, Jung Young Lee, Nam Jin Yoo, Sug Hyung Lee
    Cancer Research.2005; 65(3): 815.     CrossRef
  • Impact of the New AJCC Staging System and Adjuvant Treatment in Rectal Cancer
    Shin Ae Lee, Hyuk-Chan Kwon, Min Ah Park, Chang Kil Jung, Sung-Hyun Kim, Ki-Jae Park, Hong-Jo Choi, Hyung-Sik Lee, Mee Sook Roh, Jae-Seok Kim, Hyo-Jin Kim
    Cancer Research and Treatment.2004; 36(2): 121.     CrossRef
  • Combination Chemotherapy of Heptaplatin, Paclitaxel and 5-Fluorouracil in Patients with Advanced Gastric Cancer: a Pilot Study
    Myung-Ju Ahn, Ho-Suck Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Oh Young Lee, Ho-Soon Choi, Sung-Joon Kwon
    Cancer Research and Treatment.2004; 36(3): 182.     CrossRef
  • Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer
    S-H Lee, W K Kang, J Park, H Y Kim, J H Kim, S I Lee, J O Park, K Kim, C W Jung, Y S Park, Y-H Im, M H Lee, K Park
    British Journal of Cancer.2004; 91(1): 18.     CrossRef
  • Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma
    Jeeyun Lee, Joon Oh Park, Won Seog Kim, Se Hoon Park, Keon Woo Park, Moon Seok Choi, Joon Hyoek Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo, Jaewon Joh, Kihyun Kim, Chul Won Jung, Young Suk Park, Young-Hyuck Im, Won Ki Kang, Mark H. Lee, Keunchi
    Cancer Chemotherapy and Pharmacology.2004; 54(5): 385.     CrossRef
  • Gefitinib (ZD1839) Monotherapy as a Salvage Regimen for Previously Treated Advanced Non-Small Cell Lung Cancer
    Jinny Park, Byung Bae Park, Jee Youn Kim, Se-Hoon Lee, Soon Il Lee, Ho Young Kim, Jung Han Kim, Se Hoon Park, Kyung-Eun Lee, Joon Oh Park, Kihyun Kim, Chul Won Jung, Young Suk Park, Young-Hyuck Im, Won Ki Kang, Mark H. Lee, Keunchil Park
    Clinical Cancer Research.2004; 10(13): 4383.     CrossRef
  • A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers
    Jinny Park, Yong Chan Ahn, Hojoong Kim, Se-Hoon Lee, Se Hoon Park, Kyung-Eun Lee, Do Hoon Lim, JoonOh Park, Kihyun Kim, Chul Won Jung, Young-Hyuck Im, Won Ki Kang, Mark H. Lee, Keunchil Park
    Lung Cancer.2003; 42(2): 227.     CrossRef
  • Delta 13C‐urea breath test value is a useful indicator for Helicobacter pylori eradication in patients with functional dyspepsia
    YOUNG‐WOON CHANG, SUN‐KEE MIN, KYUNG‐JIN KIM, YO‐SEOB HAN, JOO‐HEE LEE, SEOK‐HO DONG, HYO‐JONG KIM, BYUNG‐HO KIM, JOUNG‐IL LEE, RIN CHANG
    Journal of Gastroenterology and Hepatology.2003; 18(6): 726.     CrossRef
  • Postoperative chemoradiotherapy for gastric cancer
    S.H. Park, D.Y. Kim, J.S. Heo, D.H. Lim, C.K. Park, K.W. Lee, S.H. Choi, T.S. Sohn, S. Kim, J.H. Noh, Y.I. Kim, J.O. Park, K. Kim, W.S. Kim, C.W. Jung, Y.H. Im, M.H. Lee, K. Park, C.H. Park, W.K. Kang
    Annals of Oncology.2003; 14(9): 1373.     CrossRef
  • Role of Helicobacter pylori infection among offspring or siblings of gastric cancer patients
    Young‐Woon Chang, Yo‐Seob Han, Dong‐Keun Lee, Hyo‐Jong Kim, Hyun‐Seok Lim, Jeong‐Seop Moon, Seok‐Ho Dong, Byung‐Ho Kim, Joung‐Il Lee, Rin Chang
    International Journal of Cancer.2002; 101(5): 469.     CrossRef
  • 4,942 View
  • 37 Download
  • 68 Crossref
Close layer
Retrospective Analysis of the Results of Adjuvant Chemotherapy in Breast Cancer Patients with 10 or More Positive Nodes: Nonrandomized Comparison of Adriamycin-Containing Regimens
Jin Hee Ahn, Haeseoung Bahng, Jeong Gyun Kim, Sung Bae Kim, Sei Hyun Ahn, Hyesook Chang, Jung Shin Lee, Sang Hee Kim, Woo Kun Kim
Cancer Res Treat. 2002;34(2):84-90.   Published online April 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.2.84
AbstractAbstract PDF
PURPOSE
To evaluate the results of adriamycin-based adjuvant chemotherapy with or without high dose chemotherapy (HDC) with stem cell transplantation (SCT) in breast cancer with 10 or more positive axillary nodes.
MATERIALS AND METHODS
Seventy-one breast cancer patients who had undergone surgery and had 10 or more positive axillary nodes were included in this study held between January 1997 and December 1999. The pathologic and clinical records were reviewed retrospectively.
RESULTS
Twenty-nine patients were treated with adriamycin followed by 8 courses of CMF (group I); 22 patients received 4 courses of adriamycin and 7 patients received 3 courses of adriamycin. Twenty-six patients received median 6 courses of CAF (group II) and 16 patients underwent HDC and autologous SCT (group III). With a median follow-up of 27.1 months, relapses were observed in 24 patients (33.8%) and the 3-year disease-free survival (DFS) rate was 57.1%; group I/II 55.4%, and group III 62.7%. The three-year overall survival (OS) rate was 86.1%; group I/II 83.0%, group III 93.8%. There were no difference in the 3-year DFSs or in the OSs of group I and group II. However, patients who received only 3 courses of the sequential adriamycin in group I showed a significantly poorer 3-year OS than those that received 4 courses of adriamycin (42.9% vs. 95.5%).
CONCLUSION
Our study shows that adriamycin-containing combination chemotherapy is as effective as HDC with SCT in patients with 10 or more positive axillary lymph nodes judging by 3-year DFS and OS, and shows that three courses of adriamycin seems to be inadequate.

Citations

Citations to this article as recorded by  
  • Alternative Therapy and Abnormal Liver Function During Adjuvant Chemotherapy in Breast Cancer Patients
    Jin-Hee Ahn, Sung-Bae Kim, Mi Ra Yun, Jung-Shin Lee, Yoon-Koo Kang, Woo Kun Kim
    Journal of Korean Medical Science.2004; 19(3): 397.     CrossRef
  • 3,989 View
  • 26 Download
  • 1 Crossref
Close layer
Detection of Micrometastases of Breast Cancer by Immunohistochemical Analysis of Cytokeratin
Byung Ho Son, Ju Han Lee, Jong Sang Choi
Cancer Res Treat. 2002;34(2):91-96.   Published online April 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.2.91
AbstractAbstract PDF
PURPOSE
Axillary lymph node metastases are the single most important predictor of overall survival in patients with breast cancer. Micrometastases are defined by the American Joint Committee on Cancer as tumor foci less than or equal to 2 mm in greatest dimension. Recently, up to 30% of breast cancer patients were reported to have micrometastases. In this paper, to assess the rate of micrometastases in patients with stage I breast cancer, we attempted to determine the most useful marker of the micrometastases in node negative cases by routine histopathologic examination of regional lymph nodes and comparison of the results with the influencing factors on prognosis.
MATERIALS AND METHODS
We performed immunohisto chemical staining for pancytokeratin, cytokeratin 7, cytokeratin 20 and CEA to identify which protein was the most useful marker for the detection of micrometastases in 86 node negative cases and determined the correlation between histological and clinical data.
RESULTS
A total of 5 lymph nodes in 5 separate cases showed micrometastases among the total 1,296 lymph nodes and 86 cases. The rates of micrometastases of lymph nodes and cases were 0.38% and 5.8%, respectively. The tumor type of micrometastasis was infiltrating ductal carcinoma in all cases. None of the microme tastases cases showed any relationship with tumor grade, tumor size, expression of ER and PR, patient survival rate or recurrence rate. The most useful marker to detect micrometastases was pancytokeratin.
CONCLUSION
The results of this study indicate that micrometastasis of axillary lymph nodes does not carry any independent prognostic significance.
  • 3,876 View
  • 35 Download
Close layer
Development and Test of an Information Needs Scale for Outpatients Undergoing Chemotherapy
Eun Hyun Lee, Jin Hyuk Choi, Ho Yeong Lim, Mi Sook Seo, Hugh C Kim
Cancer Res Treat. 2002;34(2):97-103.   Published online April 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.2.97
AbstractAbstract PDF
PURPOSE
The purpose of this study was to develop and test an Information Needs Scale for Korean outpatients undergoing chemotherapy (INS-C).
MATERIALS AND METHODS
Thirty-three items of the INS-C had content validity based upon findings in the literature and the experiences of expert oncology physicians and nurses. Each item consisted of a five-point Likert scale from 1 (don't want to know) to 5 (want to know very much). The items were administered to 175 Korean outpatients undergoing chemotherapy. The data obtained was analysed using a factor analysis for construct validity and Cronabch's alpha for internal consistent reliability.
RESULTS
From the factor analysis, six subscales were derived significantly. The six subscales explained 64.62% of the variance. The subscales were named Side-Effects/Investigative Tests (9 items), Spread of Disease (4 items), Financial Cost (2 items), Treatment (7 items), Activities/ Eating (6 items), and Interrelationships/Support (5 items). The Cronbach's alpha of the total INS-C was .95, and the alpha of the subscales ranged from .77 to .91.
CONCLUSION
The present study suggests that the INS-C is a reliable and valid instrument to measure the information needs of outpatients undergoing chemotherapy. Health professionals caring for patients with cancer should assess the informational needs of their patients using a reliable and valid instrument and be prepared to provide accurate information.

Citations

Citations to this article as recorded by  
  • Psychometric Evaluation of a Need Scale for Cancer Patients Undergoing Follow-up Care
    Eun-Hyun Lee, Seongmi Moon, Soo-Yeon Cho, Young Taek Oh, Mison Chun, Sung Hwan Kim, Jae-Sung Kim, Hye Kyung Kim
    Journal of Korean Academy of Nursing.2010; 40(4): 551.     CrossRef
  • 3,465 View
  • 33 Download
  • 1 Crossref
Close layer
Dietary Habit and Helicobacter pylori Infection in Early Gastric Cancer Patient
Sang Ah Lee, Daehee Kang, Weon Seon Hong, Ki Nam Shim, Jae Won Choe, Haymie Choi
Cancer Res Treat. 2002;34(2):104-110.   Published online April 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.2.104
AbstractAbstract PDF
PURPOSE
Helicobacter pylori (H. pylori) is now generally accepted to be strongly associated with the development of gastric cancer, as well as intakes of some salted foods, charred foods, etc. To evaluate the association among dietary habits, H. pylori infection, and early gastric cancer in Koreans, a hospital based case-control study was conducted. Material and Method: A total of 268 persons participated in this case-control study. Sixty nine patients were newly diagnosed as an early gastric cancer (EGC) at the Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, Seoul, Korea. One hundred ninety-nine subjects with no symptoms who visited the Health Promotion Center for their general checkups were selected as the controls. All subjects were examined for H. pylori infection, biochemical blood test the life style, and dietary habit were interviewed by a trained dietition with semi-quantitative food frequency question naire (FFQ) and adaptive salt concentration were taste evaluated.
RESULTS
H. pylori seropositivity was observed in 88.4% in cases, as compared with 74.9% in controls (OR=2.5, 95% CI: 1.1-5.7). The adaptive salt concentration was associated with early gastric cancer risk (chi-squir=50.8, p<0.001). The analysis of food intake frequency demonstrated that early gastric cancer risk was reduced by the intake of clear soups, raw vegetables, fruits and juices, beef with vegetables and soybean curds. On the other hand, high intake of salt-fermented fish and kimchi elevated the risk of early gastric cancer.
CONCLUSION
These results suggest that some dietary factors and H. pylori infection have a significant association with the development of early gastric cancer.

Citations

Citations to this article as recorded by  
  • Dietary intake and cancer incidence in Korean adults: a systematic review and meta-analysis of observational studies
    Ji Hyun Kim, Shinyoung Jun, Jeongseon Kim
    Epidemiology and Health.2023; 45: e2023102.     CrossRef
  • Effect of dietary vitamin C on gastric cancer risk in the Korean population
    Bach Viet Hoang, Jeonghee Lee, Il Ju Choi, Young-Woo Kim, Keun Won Ryu, Jeongseon Kim
    World Journal of Gastroenterology.2016; 22(27): 6257.     CrossRef
  • Epidemiology and screening of gastric cancer in Korea
    Minkyo Song, Hwi-Won Lee, Daehee Kang
    Journal of the Korean Medical Association.2015; 58(3): 183.     CrossRef
  • Gastric Cancer Epidemiology in Korea
    Aesun Shin, Jeongseon Kim, Sohee Park
    Journal of Gastric Cancer.2011; 11(3): 135.     CrossRef
  • Fresh and pickled vegetable consumption and gastric cancer in Japanese and Korean populations: A meta‐analysis of observational studies
    Hyun Ja Kim, Sun Young Lim, Jung‐Sug Lee, Sohee Park, Aesun Shin, Bo Youl Choi, Taichi Shimazu, Manami Inoue, Shoichiro Tsugane, Jeongseon Kim
    Cancer Science.2010; 101(2): 508.     CrossRef
  • Identifying the Risk Factors Through the Development of a Predictive Model for Gastric Cancer in South Korea
    Dong-Suk Lee, Han-Kwang Yang, Jong-Won Kim, Jeong-Whan Yook, Seong-Hoon Jeon, Sung-Hak Kang, Young-Ju Kim
    Cancer Nursing.2009; 32(2): 135.     CrossRef
  • 5,305 View
  • 61 Download
  • 6 Crossref
Close layer
Phase II Trial of Gemcitabine, UFT-E, Leucovorin Combination Chemotherapy in Advanced Pancreatic Adenocarcinoma
So Young Yoon, Kyong Hwa Park, Sang Chul Oh, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Jae Seon Kim, Chang Duck Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim
Cancer Res Treat. 2002;34(2):111-116.   Published online April 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.2.111
AbstractAbstract PDF
PURPOSE
To evaluate the efficacy and toxicity of a Gemcitabine, UFT-E, Leucovorin combination chemotherapy in the treatment of advanced pancreatic adenocarcinoma. PATIENTS AND METHODS: Patients <=70 years, with no prior chemotherapy and with bidimensionally measurable advanced pancreatic adenocarcinoma, ECOG performance status <=2, and adequate bone marrow, kidney, and liver function were eligible for this trial. Eligibility criteria for clinical benefit assessment were pain with at least a daily analgesic consumption of two nonsteroidal anti-inflammatory drugs or a Karnofsky performance status between 50 and 70. Treatment consisted of 1,000 mg/m2 of Gemcitabine on days 1, 8 and 15, repeated every 4 weeks, with UFT-E administered orally 500 mg-700 mg by body surface area (BSA). Leucovorin was administered 45 mg/day orally. Dosages of UFT-E and Leucovorin were divided and administered three times per day from day 1 to day 21. After 7 days of rest, UFT-E and Leucovorin were administered repeatedly.
RESULTS
Twenty-three patients were enrolled between April 1999 to April 2000. Eighty two cycles (median, four cycles) were delivered to all patients. The objective response rate was 15.8% in 19 assessable patients and 13.0% in the intent-to-treat population. Twelve patients (57.9%) displayed stable disease. Grade 3 or 4 neutropenia occurred in 30.4% of patients, nausea/vomiting in 8.3%, diarrhea in 4.3%, and mucositis in 4.3%. The median time to progression was 8 months. The median survival was 8 months in the assessable population and 6 months in the intent-to-treat population Clinical benefit was achieved in 11 (57.9%) of 19 assessable patients.
CONCLUSION
Gemcitabine, UFT-E, Leucovorin combination chemotherapy is a well-tolerated and safe regimen in cases of advanced pancreatic adenocarcinoma. Although the response rate is low, it shows a survival benefit and clinical benefit and deserves further evaluation in a phase III trial.

Citations

Citations to this article as recorded by  
  • Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study
    Kyung Hee Lee, Min Kyoung Kim, Yeol Hong Kim, Baek Yeol Ryoo, Ho Yeong Lim, Hong Suk Song, Hoon Kyo Kim, Myung Ah Lee, Seock Ah Im, Heung Moon Chang, Jae Yong Cho, Dae Young Zang, Bong Seog Kim, Jun Suk Kim
    Cancer Chemotherapy and Pharmacology.2009; 64(2): 317.     CrossRef
  • 4,552 View
  • 18 Download
  • 1 Crossref
Close layer
Immunohistochemical Study of beta-catenin Expression between Hepatocellular Carcinoma and Cholangiocarcinoma
Ki Jung Yun, Weon Cheol Han, Suck Chei Choi, Tae Hyeon Kim
Cancer Res Treat. 2002;34(2):117-121.   Published online April 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.2.117
AbstractAbstract PDF
PURPOSE
beta-catenin is an intracellular protein that is an integral component of the cadherin-mediated cell-cell interaction and a downstream transcriptional activator in the wnt signal transduction pathway. Inappropriate activation of beta-catenin has recently been implicated in the development of hepatocellular carcinoma and cholangiocarcinoma. Nuclear beta-catenin expression is strongly associated with gene mutation. This study was designed to evaluate the pattern of beta-catenin expression between hepatocellular carcinoma and cholangiocarcinoma.
MATERIALS AND METHODS
Immunohistochemical expression of beta-catenin was studied in 7 normal livers, 33 hepatocellular carcinomas and 20 cholangiocarcinomas, that were formalin fixed and paraffin embedded.
RESULTS
beta-catenin was expressed mainly in the cytoplasmic membrane of the normal hepatocytes and bile ducts. Nuclear expressions, not noted in the normal liver, were noted in 30% of the hepatocellular carcinomas and 10% of the cholangiocarcinomas. And, nuclear expression was more common in the high grade (50%) hepatocellular carcinomas than the low grade (18%) hepatocellular carcinomas (p<=0.05).
CONCLUSION
The above results indicate that nuclear expression of beta-catenin is observed in the carcinoma but not the normal liver, and is associated with high grade liver carcinoma.

Citations

Citations to this article as recorded by  
  • Guanine nucleotide exchange factor T exerts the cancer-promoting function in cholangiocarcinoma by enhancing the Wnt-GSK-3β-β-catenin cascade via regulation of Rac1/Cdc42
    Xifang Wang, Xiaomin Zhang, Jingying Sun, Yang Sun, Yuan Zhang, Li He, Ping Wang, Feng Li, Chao Sun
    Toxicology and Applied Pharmacology.2023; 467: 116492.     CrossRef
  • Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity
    Elisa Lozano, Paula Sanchon-Sanchez, Ana Morente-Carrasco, Luis Miguel Chinchilla-Tábora, José L. Mauriz, Paula Fernández-Palanca, Jose J. G. Marin, Rocio I. R. Macias
    Cells.2023; 12(8): 1141.     CrossRef
  • Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma
    Guo-Feng Zhang, Ling Qiu, Shu-Li Yang, Jia-Cheng Wu, Tong-Jun Liu
    Bioscience Reports.2020;[Epub]     CrossRef
  • β-Catenin expression is associated with cell invasiveness in pancreatic cancer
    Jin Niang Nan, Ok Ran Kim, Myung Ah Lee
    The Korean Journal of Internal Medicine.2019; 34(3): 618.     CrossRef
  • A Role for the WNT Co-Receptor LRP6 in Pathogenesis and Therapy of Epithelial Cancers
    Jennifer Raisch, Anthony Côté-Biron, Nathalie Rivard
    Cancers.2019; 11(8): 1162.     CrossRef
  • Beta-Catenin Downregulation Contributes to Epidermal Growth Factor-induced Migration and Invasion of MDAMB231 Cells
    Arang Kwon, Hyun-Jung Park, Jeong-Hwa Baek
    International Journal of Oral Biology.2018; 43(3): 161.     CrossRef
  • Genetic alterations of Wnt signaling pathway–associated genes in hepatocellular carcinoma
    Young‐Dae Kim, Chang‐Hwan Park, Hyun‐Soo Kim, Sung‐Kyu Choi, Jong‐Sun Rew, Dong‐Yi Kim, Yang‐Suk Koh, Kyung‐Woon Jeung, Kyung‐Hwa Lee, Ji‐Shin Lee, Sang‐Woo Juhng, Jae‐Hyuk Lee
    Journal of Gastroenterology and Hepatology.2008; 23(1): 110.     CrossRef
  • 4,432 View
  • 47 Download
  • 7 Crossref
Close layer
The Effects of Insulin-like Growth Factor-I (IGF-I) in Mouse Lung Cancer Cells
Seung Min Kwak, Se Kyu Kim, Sung Kyu Kim, Chul Ho Cho
Cancer Res Treat. 2002;34(2):122-127.   Published online April 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.2.122
AbstractAbstract PDF
PURPOSE
Insulin-like growth factor-I (IGF-I) is an important mitogen in many types of malignancies. The purpose of this study was to evaluate the role of the IGF system on cell proliferation and cell death in mouse lung cancer cell lines (3LL).
MATERIALS AND METHODS
Northern analysis was performed in 3LL cells. We evaluated the phosphorylation of IGF-I receptor (IGF-IR) with IGF-I stimulation. MTT assay was performed after treating 3LL cells with IGF-I and the treatment effect on cell death in the presence of anticancer drug was investigated.
RESULTS
Northern analysis revealed the presence of IGF-I and IGF-IR mRNA expression in 3LL cells. IGF-I increased cellular proliferation in serum free media. IGF-I also stimulated the tyrosine phosphorylation of two proteins: one, with a molecular mass of 95 kDa, was the beta-subunit of IGF-IR; the other, with an approximate molecular mass of 185 kDa, was originally identified as the insulin receptor substrate-I (IRS-I). IGF-I at a low concentration inhibited the cell death induced by adriamycin.
CONCLUSION
IGF-I, a mitogen through the phosphorylation of the IGF-IR beta-subunit, acts as a survival factor to inhibit cell death. Therefore, these findings suggest that IGF-I and IGF-IR are involved in both the cell proliferation and cell death associated with cancer cell growth.
  • 3,877 View
  • 23 Download
Close layer
5-FU Induces Apoptosis of Fas (+), HepG2 Cells Via Activation of Fas-mediated Caspase and Mitochondria Dysfunction
Channy Park, Kui hyun Yoon, Young Jin Lee, Yong Kweon Kim, Yee Cheon Choi, Jae Hoon Shin, Jeong Hwan Cho, RaeKil Park
Cancer Res Treat. 2002;34(2):128-138.   Published online April 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.2.128
AbstractAbstract PDF
PURPOSE
In order to investigate the role of Fas on the chemosensitivity of cancer cells in regards to chemotherapeutic agents, the Fas/FasL signaling pathway of apoptosis was explored in human hepatoma cells.
MATERIALS AND METHODS
Fas expression of hepatoma cells including Chang, Huh7, HepG2, and Hep3B cells, was determined by RT-PCR and flow cytometry analysis. Cell viability was measured by MTT assay and apoptosis was assessed by DNA fragmentation assay. The catalytic activity of the caspase-family proteases including caspase-3, 6, 8, and 9 proteases, was tested using fluorogenic biosubstrates. The expression of apoptotic mediators including cytochrome c, PARP, and Bcl2 family proteins were measured from cytosolic and mitochondrial compartments. Mitochondrial membrane potential was measured by fluorescence staining with JC-1, rhodamine 123.
RESULTS
Fas mRNA was constitutively expressed in Chang and HepG2 as defined as Fas (+) cells, but not in Huh7 and Hep3B cells, defined as Fas (-) cells. Fas (+) cells were markedly sensitive to 5-FU whereas Fas (-) cells were resistant and able to survive. 5-FU increased Fas expression of Fas (+) HepG2 cells and simultaneously resulted in apoptotic death, characterized by the ladder-pattern fragmentation of genomic DNA. Moreover, it increased the catalytic activity of caspase-8 protease, which eventually cleaved the Bid into truncated Bid which translocated into mitochondria only in Fas (+) cells. It also increased the caspase-9 protease activity with Bax expression, cytosolic release of cytochrome c, and mytochondrial dysfunction only in Fas (+) HepG2 cells. Furthermore, 5-FU increased the enzymatic activity of caspase-3 protease with PARP digestion in HepG2 cells.
CONCLUSION
5-FU exerted cytotoxicity against hepatoma cells via activation of Fas-mediated apoptotic signaling including caspase cascades and mytochondrial dysfunction. Our data suggests that Fas may be an important modulator of the chemosensitivity of cancer cells vis- -vis anticancer chemotherapeutic agents.

Citations

Citations to this article as recorded by  
  • Sex-dependent liver cancer xenograft models for predicting clinical data in the evaluation of anticancer drugs
    Sungryong Oh, Joohee Jung
    Laboratory Animal Research.2021;[Epub]     CrossRef
  • Lead bioactive compounds of Aloe vera as potential anticancer agent
    Ranabir Majumder, Chandan Kanta Das, Mahitosh Mandal
    Pharmacological Research.2019; 148: 104416.     CrossRef
  • Extract from Artemisia annua Linn? Induces Apoptosis through the Mitochondrial Signaling Pathway in HepG2 Cells
    Bo Min Kim, Guen Tae Kim, Eun Ji Kim, Eun Gyeong Lim, Sang-Yong Kim, Young Min Kim
    Journal of the Korean Society of Food Science and Nutrition.2016; 45(12): 1708.     CrossRef
  • Dexamethasone Inhibits TRAIL- and Anti-cancer Drugs-induced Cell Death in A549 Cells through Inducing NF-κB-independent cIAP2 Expression
    Youn Seup Kim, Jae Seuk Park, Young Koo Jee, Kye Young Lee
    Cancer Research and Treatment.2004; 36(5): 330.     CrossRef
  • 4,675 View
  • 56 Download
  • 4 Crossref
Close layer
Treatment Results of Postoperative Radiation Therapy for Malignant and Atypical Meningioma
Sang Min Yoon, Seung Do Ahn, Hyesook Chang, Eun Kyung Choi, Jong Hun Kim, Sang wook Lee, Chang Jin Kim, Jung Hun Kim, Byung Deuk Kwon
Cancer Res Treat. 2002;34(2):139-144.   Published online April 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.2.139
AbstractAbstract PDF
PURPOSE
We evaluated the survival rate, prognostic factors and patterns of failure in malignant and atypical meningiomas, and investigated the role of radiation therapy in the treatment of these tumors.
MATERIALS AND METHODS
We retrospectively reviewed nineteen patients treated at Asan Medical Center between Mar. 1994 and Jun. 2000 with histologically confirmed malignant or atypical meningiomas. The median patient age was 52 years. The extent of surgery prior to radiation was gross total resection in 13 and subtotal resection in 6. Eleven patients were referred for radiation immediately after diagnosis and the remainder after at least one recurrence. All patients received megavoltage radiation to a median dose of 55.8 Gy. The median follow-up period was 41 months.
RESULTS
Eleven patients (57.9%) showed no evidence of disease, five patients died of meningioma and three were alive with disease. The 5-year overall and relapse-free survivals were 75.9 and 50.6%, respectively. There were no statistically significant prognostic factors found to be associated with relapse-free survival by univariate or multivariate analysis. During the follow-up period, no significant treatment-related complications were detected.
CONCLUSION
The major patterns of failure were in-field recurrence. In order to reduce local failure, a higher radiation dose may be needed and a high precision therapy should be considered.

Citations

Citations to this article as recorded by  
  • Revisiting Adjuvant Radiotherapy After Gross Total Resection of World Health Organization Grade II Meningioma
    Christopher S. Graffeo, Heather E. Leeper, Avital Perry, Joon H. Uhm, Daniel J. Lachance, Paul D. Brown, Daniel J. Ma, Jamie J. Van Gompel, Caterina Giannini, Derek R. Johnson, Aditya Raghunathan
    World Neurosurgery.2017; 103: 655.     CrossRef
  • 4,377 View
  • 40 Download
  • 1 Crossref
Close layer
MINE (mesna, ifosfamide, mitoxantrone, etoposide) Chemotherapy as a Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Seong Hoon Chang, Yang Soo Kim, Wan Kyu Eo
Cancer Res Treat. 2002;34(2):145-152.   Published online April 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.2.145
AbstractAbstract PDF
PURPOSE
The prognosis of non-Hodgkin's lymphoma (NHL) is disappointing for patients who experience primary treatment failure or relapse after an initial response. Patients in relapse may respond again to chemotherapy, however the time to disease progression becomes shorter and eventually the disease becomes resistant. The aim of this study was to evaluate the efficacy and safety of the MINE regimen in the treatment of patients with relapsed or refractory NHL. Material and Methods: Forty-three pretreated patients with a median age of 56 years were enrolled into the study between October 1995 and June 2000. Most patients (60.5%) had a performance status of 0 to 1, and a diffuse large cell subtype (55.8%). Seventy-four percent of patients had stage III or IV disease at the start of MINE treatment. Eighteen (41.9%) patients had complete response, 5 (11.6%) had partial response, and 20 (46.5%) had failed to respond to prior therapy. Ifosfamide 4 g/m2 was divided over 3 days and administered IV over a 1 hour period. Mitoxantrone 8 mg/m2 was administered as a short IV infusion on day 1. Etoposide (65 mg/m2/day) was infused over 1 hour on days 1 to 3. A total of 144 cycles was administered, with a mean of 3.34 cycles per patient (range, 1-8). The mean relative dose intensity was 87.4%.
RESULTS
1) Nine patients achieved a complete response and nine patients achieved a partial response, resulting in an overall response rate of 43.8% of the 41 assessable patients. 2) The median survival time was 6 months (95% CI, 4 to 8 months), and the median time to failure was 5 months (95% CI, 3 to 7 months). 3) A statistically significant association with complete response rates was found for complete response to prior therapy (p=0.049). The significant factors for overall survival were a complete response after MINE chemotherapy and serum 2-microglobulin (p=0.003, p=0.012, respectively). The significant factors for time to treatment failure were a complete response after MINE chemotherapy and serum 2-microglobulin (p=0.003, p=0.044, respectively). 4) The main result of toxicity of MINE was bone marrow suppression.
CONCLUSION
The response to MINE chemotherapy and serum 2-microglobulin were both independent prognostic factors for overall survival and time to treatment failure. As the median time to treatment failure for complete responses was 14 months, the best use of this regimen could be in a strategy that includes prompt consolidation of a complete response with intense chemotherapy, with or without hematopoietic stem cell rescue.

Citations

Citations to this article as recorded by  
  • Clinical feasibility of oral low-dose etoposide and sobuzoxane for conventional chemotherapy–intolerant lymphoma patients
    Akihiro Ohmoto, Shigeo Fuji
    Expert Review of Anticancer Therapy.2021; 21(7): 715.     CrossRef
  • 5,754 View
  • 169 Download
  • 1 Crossref
Close layer
Gastrosplenic Fistula Complicated in a Patient with Non- Hodgkin's Lymphoma
Seong Eun Yang, Jong Youl Jin, Chi Won Song, Ji Chan Park, Jee In Lee, Wook Kim, Jeana Kim, Hae Giu Lee
Cancer Res Treat. 2002;34(2):153-156.   Published online April 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.2.153
AbstractAbstract PDF
Reported cases of gastrosplenic fistulas are extremely rare in the literature. Malignancy is the primary cause in 50% of patients, followed by perforated peptic ulcer (40%). Fistulas can cause spleen rupture and potential bleeding that threaten the life of the patient. Lymphoma is the most common cause of malignancy complicated with gastrosplenic fistula. Most gastrosplenic fistulae caused by lymphoma eventually close following chemotherapy, although splenectomy should be performed to avoid further complications. We experienced a case of non-Hodgkin's lymphoma complicated with gastrosplenic fistula in a 21 year-old man. He was admitted to our hospital because of LUQ mass. On the abdominal CT, a splenic mass with central necrosis and gas was discovered. The biopsy specimen of the stomach and spleen displayed diffuse, large B cell type non-Hodgkin's lymphoma. After one cycle of CHOP chemotherapy, the LUQ mass was markedly regressed although the gastrosplenic fistula was still present on the follow-up CT. The fistula was treated by splenectomy and a partial resection of gastric fundus. Follow-up chemotherapy was continued after surgery.

Citations

Citations to this article as recorded by  
  • SPONTANEOUS GASTROSPLENIC FISTULA: AN UNUSUAL PRESENTATION OF DIFFUSE LARGE B CELL LYMPHOMA
    Hale Bülbül, Kader Irak, Selin Berk, Yusuf Ulusoy, Mesut Ayer
    Gastroenterology Nursing.2022; 45(1): 63.     CrossRef
  • Gastro-Splenic Fistula Related to Large B Cell Lymphoma
    Diana Triantafyllopoulou, Ioannis Gkikas, Jagdish Adiyodi, Iain Crossingham, Shofiq Al-Islam, Muhammad Shahbaz Alam, Neil Sahasrabudhe, Ambareen Kausar, Ali Bin Ayub, Hazel Cowburn, Lisa Fox, Maqsood Punekar, Marian Macheta, Reuben Tooze
    Reports.2020; 3(2): 17.     CrossRef
  • Hand-assisted laparoscopic approach for the treatment of gastrosplenic fistula: A case report and review of the literature
    Virginia Gallo, Luigi Pugliese, Francesco S. Latteri, Andrea Peri
    Laparoscopic, Endoscopic and Robotic Surgery.2020; 3(4): 120.     CrossRef
  • Successful Treatment of Gastrosplenic Fistula Arising from Diffuse Large B-Cell Lymphoma with Chemotherapy: Two Case Reports
    Makoto Saito, Kencho Miyashita, Yosuke Miura, Shinpei Harada, Reiki Ogasawara, Koh Izumiyama, Akio Mori, Masanori Tanaka, Masanobu Morioka, Takeshi Kondo
    Case Reports in Oncology.2019; 12(2): 376.     CrossRef
  • Gastrosplenic fistula occurring in lymphoma patients: Systematic review with a new case of extranodal NK/T-cell lymphoma
    Dong Hyeok Kang, Jimi Huh, Jong Hwa Lee, Yoong Ki Jeong, Hee Jeong Cha
    World Journal of Gastroenterology.2017; 23(35): 6491.     CrossRef
  • Lymphoma Causing Gastrosplenic Fistula Revealed by FDG PET/CT
    Trent P. Wang, Mohan Doss, Jeffrey L. Tokar, Sanjay Reddy, Stefan K. Barta, Jian Q. Yu
    Clinical Nuclear Medicine.2017; 42(11): 890.     CrossRef
  • Gastrosplenic Fistula From Hodgkin's Lymphoma
    Carolyn D. Seib, Flavio G. Rocha, Dick G. Hwang, Brent T. Shoji
    Journal of Clinical Oncology.2009; 27(20): e15.     CrossRef
  • 4,181 View
  • 46 Download
  • 7 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP